In today's stock market news, CRH plc (NYSE: CRH) has successfully completed the final phase of its European lime divestment, finalizing an agreement to divest its lime operations in Europe for approximately $1.1 billion. This transaction includes the Group's lime operations in Poland, effectively concluding CRH's strategic efforts to optimize its portfolio by shedding non-core assets. Read More
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced promising results from its pivotal Phase 3 PALISADE study for plozasiran, a treatment for familial chylomicronemia syndrome (FCS). The study achieved its primary endpoint, showcasing an impressive 80% reduction in triglycerides from baseline and an 83% reduction in acute pancreatitis risk. Arrowhead plans to file a New Drug Application by year-end 2024, reflecting its commitment to advancing this innovative treatment. Read More
In a significant development for the tech industry, Sify Technologies (NASDAQ: SIFY) has become India's first NVIDIA DGX-Ready Data Center certified partner for liquid cooling technology. This certification supports a 130 KW/rack capacity, validating Sify's data center deployment solution for high-density supercomputing. Sify's CEO, Sharad Agarwal, emphasized that this achievement positions the company to provide comprehensive NVIDIA DGX-powered colocation along with advanced AI and data science solutions, making them a key player in the emerging AI ecosystem. Read More
In another noteworthy event, Nyxoah SA (NASDAQ: NYXH) rang the Nasdaq Closing Bell as it prepares for the U.S. market launch of its innovative sleep apnea device, the Genio® device. The company has completed its FDA regulatory submission and is on track for U.S. approval by the end of 2024. Key highlights include positive data from the pivotal DREAM study and robust funding of over €85 million for the market entry. Read More
Furthermore, Moderna (NASDAQ: MRNA) has received approval from the Taiwan Food & Drug Administration for an updated formulation of its COVID-19 mRNA vaccine Spikevax, specifically targeting the SARS-CoV-2 variant JN.1. This approval aligns with the World Health Organization's recommendations and enhances Moderna's efforts to combat COVID-19 globally, with additional regulatory decisions anticipated shortly. Read More
In notable legal news, the Schall Law Firm has announced an investigation into Tyra Biosciences, Inc. (NASDAQ: TYRA) for potential violations of securities laws. The investigation focuses on whether Tyra issued false or misleading statements or failed to disclose key information to investors. Shareholders who suffered losses are encouraged to participate in the inquiry, highlighting the firm's commitment to protecting investor rights. Read More
Lastly, Praxis Precision Medicines (NASDAQ: PRAX) has announced it will release topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) on September 3, 2024, focusing on SCN2A and SCN8A Developmental and Epileptic Encephalopathies. Following the announcement, the company will host a conference call and webcast presentation to discuss the results, marking a crucial step for Praxis in developing therapies for central nervous system disorders. Read More
Additionally, Nordic American Tankers Ltd (NYSE: NAT) has announced an upcoming Investor Conference Call scheduled for Thursday, September 12, 2024, at 8 AM Eastern Standard Time (EST) / 2 PM Central European Time (CET). This conference aims to provide shareholders and investors with an update on the company's current status and future prospects. Details for dial-in participation will be released later. Read More
